The New Formulations of Immunoglobulin Replacement Therapies and Future Aspects

In the past six decades, significant progress has been made in refining the dosing, processing, and methods of administering IgRT for IEI.Intravenous (IV) immunoglobulin has demonstrated its efficacy as a treatment approach, typically given every 3 to 4 weeks.Nonetheless, some patients encounter challenges due to systemic side effects, fluctuations in IgG levels, wear-off effects, difficulties with IV access, hospital visits, and work